Skip to content Skip to footer
Subscribe Now
VIEWPOINTS_Richard Stefanacci_2024
VIEWPOINTS

Neurogenerative Disorders Management: Richard Stefanacci of TauRx in an Enlightening Conversation with PharmaShots

Shots:  Richard Stefanacci, Chief Medical Officer at TauRx, sheds light on the anti-tau drug Hydronomethylthionine mesylate (HMTM), a potential oral treatment for patients with Alzheimer’s disease and mild cognitive impairment  While highlighting the positive results from the LUCIDITY P-III study, Richard speaks about bridging the gap in AD and MCI treatment by lowering the dependence…
March 18, 2024

Read more

VIEWPOINTS_Marisa Cruz_2023
VIEWPOINTS

Marisa Cruz, in an insightful conversation with PharmaShots, discusses the Empatica Health Monitoring Platform (EHMP)

Shots:  Marisa Cruz, MD, and Chief Medical Officer at Empatica, exchanged thoughts with PharmaShots on the revolutionary Empatica Health Monitoring Platform (EHMP)   Approved by the FDA in Nov’2022, EHMP leverages a cloud-based online portal to collect continuous and seamless physiological data from home and clinical setting   While conversing in great depth about Empatica’s EmbracePlus smartwatch,…
November 2, 2023

Read more

Viewpoint_Peony_Yu_2020
VIEWPOINTS

PharmaShots Interview: FibroGen’s Peony Yu Shares Insight on Roxadustat

In a recent interview with PharmaShots, Peony Yu, Chief Medical Officer of FibroGen shared her insights and highlights on data of Roxadustat Shots: FibroGen presented new efficacy and safety analyses from the roxadustat global P-III program at ASN Kidney Week 2020 Reimagined. FibroGen and its partners, AstraZeneca and Astellas, presented 42 abstracts, including 2 late-breaker poster presentations,…
December 7, 2020

Read more